Riva Therapeutics develops precision lethal small-molecule therapeutics that target essential tumor cell processes informed by genomic dependencies, aiming to treat a significant portion of cancer patients. Their approach addresses the need for effective and well-tolerated oncology medicines that extend beyond traditional DNA damage repair mechanisms.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancer treatments rely on DNA damage repair mechanisms, which can be ineffective for a significant portion of patients due to tumor heterogeneity and resistance. There is a need for oncology medicines that target essential tumor cell processes beyond traditional DNA damage repair pathways.
Solution
Riva Therapeutics is developing precision-lethal small-molecule therapeutics that selectively target essential tumor cell processes based on genomic dependencies. Their approach aims to create transformative medicines for cancer patients by going beyond DNA damage repair mechanisms. These therapies are designed to provide profound clinical activity and be well-tolerated, with the goal of substantially improving patient lives. By leveraging deep knowledge of genomic dependencies, Riva Therapeutics is working to discover a new generation of oncology medicines suitable for large patient populations.
Target Audience
The primary target audience includes cancer patients who are not effectively treated by traditional DNA damage repair-based therapies, as well as oncologists seeking more effective and well-tolerated treatment options.
Features
- Small molecule therapeutics targeting essential tumor cell processes
- Focus on genomic dependencies to selectively target cancer cells
- Designed for high efficacy and improved tolerability